Angiotech announces new appointments to executive management team
19 Dezember 2005 - 8:30PM
PR Newswire (US)
VANCOUVER, Dec. 19 /PRNewswire-FirstCall/ -- Angiotech
Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP) today
announced new internal appointments to its executive management
team, including the creation of three new roles: Chief Compliance
Officer, Chief Medical Officer, and Chief Clinical and Regulatory
Affairs Officer. "These new appointments to our executive
management team were made in order to support the growth and
operational focus of our company as we bring the next generations
of novel drug-device and drug-biomaterial combination products to
market," said Dr. William L. Hunter, President and CEO of
Angiotech. Dr. Hunter added, "We are pleased to announce that all
of these promotions were made from within the existing Angiotech
management team, and reflect our commitment to developing and
building upon our leadership skills." Mr. David Hall has been
appointed to the newly-created position of Chief Compliance Officer
and added responsibility as Senior Vice President, Government and
Community Relations. Most recently as Chief Financial Officer at
Angiotech, Mr. Hall led the adoption and implementation of the
company's Sarbanes-Oxley (SOX) compliance measures. In this new
role, he will also act as a key liaison with government and
community agencies. The creation of this senior position
demonstrates Angiotech's continued commitment to regulatory
compliance and corporate governance. Mr Hall also remains Corporate
Secretary and Treasurer. Mr. Thomas Bailey has been appointed Chief
Financial Officer. Formerly Vice President, Business Development,
Mr. Bailey will continue to oversee Angiotech's business
development strategy and strategic alliances, in addition to
managing the company's overall financial and accounting activities.
Mr. Bailey brings extensive experience in corporate growth
initiatives such as acquisitions, corporate alliances and
partnerships within biotechnology, pharmaceutical and medical
device companies. Dr. Rui Avelar has been promoted to the new
position of Chief Medical Officer. Most recently Dr. Avelar was
Senior Vice President, Medical Affairs and Communications. Dr.
Avelar's background includes both extensive clinical experience as
a practicing physician and knowledge of the pharmaceutical industry
through his previous work as a securities analyst. Building on his
existing responsibilities, Dr. Avelar will continue to oversee the
company's medical market analysis and provide strategic leadership
in the product development process. Dr. Gary Ingenito has been
appointed to the newly-created role of Chief Clinical and
Regulatory Affairs Officer in recognition of his contributions as
Senior Vice President, Clinical and Regulatory Affairs at
Angiotech. In his new role, he will continue to provide direction
for the company's worldwide clinical and regulatory activities. He
will also take on the role of Senior Vice President of Product
Development, coordinating R&D, clinical and operational
activities. Dr. Ingenito brings a wealth of expertise to this role
from his many years of experience in the pharmaceutical industry
and with clinical research organizations. Additional biographical
detail on Angiotech's senior management is available on the
company's website at http://www.angiotech.com/. Vancouver-based
Angiotech Pharmaceuticals, Inc. is a specialty pharmaceutical
company pioneering the combination of pharmaceutical compounds with
medical devices and biomaterials to both create novel solutions for
poorly addressed disease states and dramatically improve surgical
outcomes. To find out more about Angiotech Pharmaceuticals, Inc.
(NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please visit our website at
http://www.angiotech.com/. Statements contained herein that are not
based on historical or current fact, including without limitation
statements containing the words "anticipates," "believes," "may,"
"continue," "estimate," "expects," and "will" and words of similar
import, constitute "forward-looking statements" within the meaning
of the U.S. Private Securities Litigation Reform Act of 1995. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Such factors include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which the Company operates;
technology changes; competition; changes in business strategy or
development plans; the ability to attract and retain qualified
personnel; existing governmental regulations and changes in, or the
failure to comply with, governmental regulations; liability and
other claims asserted against the Company; and other factors
referenced in the Company's filings with the United States
Securities and Exchange Commission or the Canadian securities
regulators. Given these uncertainties, readers are cautioned not to
place undue reliance on such forward-looking statements. The
Company does not assume the obligation to update any
forward-looking statements. FOR ADDITIONAL INFORMATION:
--------------------------- Analysts and Investors: Todd Young,
Vice President Investor Relations and Communications, Angiotech
Pharmaceuticals, Inc. (604) 221-7676 ext 6933 Media: Colleen
Beauregard, Waggener Edstrom Bioscience, (503) 443-7863, Email:
DATASOURCE: Angiotech Pharmaceuticals, Inc. CONTACT: Analysts and
Investors: Todd Young, Vice President Investor Relations and
Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7676 ext
6933; Media: Colleen Beauregard, Waggener Edstrom Bioscience, (503)
443-7863, Email:
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024